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Abstract
Background: Fine needle aspiration biopsy has become a standard approach for diagnosis of peripheral
tuberculous lymphadenitis. The aim of this study was to compare the performance of Xpert MTB/RIF and Ustar
EasyNAT TB IAD nucleic acid amplification assays, against acid-fast bacilli microscopy, cytology and mycobacterial
culture for the diagnosis of TB lymphadenitis in children from a TB-endemic setting in Tanzania.
Methods: Children of 8 weeks to 16 years of age, suspected of having TB lymphadenitis, were recruited at a district
hospital in Tanzania. Fine needle aspirates of lymph nodes were analysed using acid-fast bacilli microscopy, liquid
TB culture, cytology, Xpert MTB/RIF and EasyNAT. Latent class analysis and comparison against a composite
reference standard comprising “culture and/or cytology” was done, to assess the performance of Xpert MTB/RIF and
EasyNAT for the diagnosis of TB lymphadenitis.
Results: Seventy-nine children were recruited; 4 were excluded from analysis. Against a composite reference
standard of culture and/or cytology, Xpert MTB/RIF and EasyNAT had a sensitivity and specificity of 58 % and 93 %;
and 19 % and 100 % respectively. Relative to latent class definitions, cytology had a sensitivity of 100 % and
specificity of 94.7 %.
Conclusions: Combining clinical assessment, cytology and Xpert MTB/RIF may allow for a rapid and accurate
diagnosis of childhood TB lymphadenitis. Larger diagnostic evaluation studies are recommended to validate these
findings and on Xpert MTB/RIF to assess its use as a solitary initial test for TB lymphadenitis in children.
Keywords: Mycobacterium tuberculosis, Lymphadenitis, Childhood, Fine needle aspiration, Nucleic acid
amplification, Xpert MTB/RIF, Ustar EasyNAT, Culture, Cytology, Ziehl-Neelsen
Background
Paediatric tuberculosis (TB) contributes considerably to
the global burden of TB disease. The World Health
Organization (WHO) reported that of the 9.6 million in-
cident cases in 2014, an estimated 10.4 % (1 million)
were children [1]. Other groups however, estimated the
TB incidence for the same year, as between 200,000 and
970,000 new cases [2–4]. The large variation of those es-
timates illustrates the difficulties in assessing the disease
burden in children, as recording and reporting of paedi-
atric cases is often imperfect and ultimate confirmation
of TB diagnosis is still a challenge.
Reasons for the difficulties in diagnosing TB in chil-
dren are manifold: respiratory specimens from younger
children are difficult to obtain, Mycobacterium tubercu-
losis (M. tuberculosis) is often not detectable in pauciba-
cillary paediatric specimens and host biomarkers are not
yet in place to reliably identify children with TB disease
[5, 6]. Moreover, symptoms and radiological features are
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non-specific and overlap with those of other diseases,
such as pneumonia, malnutrition or HIV-associated dis-
eases. The tuberculin skin test (TST), which indicates
TB infection, can guide clinicians in their decisions, but
does not confirm TB disease [7]. Hence, better diagnos-
tic tests for both pulmonary and extrapulmonary paedi-
atric TB are urgently needed.
Extrapulmonary TB (EPTB) constitutes up to half of
all paediatric TB cases, predominantly in children of
young age and with HIV infection [8, 9]. The most com-
mon manifestation of EPTB in children is tuberculous
lymphadenitis (TB lymphadenitis) in about two thirds of
EPTB cases, followed by central nervous system involve-
ment (meningitis), pleural, disseminated and skeletal TB
[9]. TB lymphadenitis may be mediastinal, intra-
abdominal or, as was the focus of this study, peripheral.
This form is typically superficial, and often presents as a
non-specific swelling which may be mistaken for malig-
nant in nature [10]. Previous studies in East-African
adults show that peripheral lymphadenitis is frequently
caused by non-tuberculous mycobacteria or M. bovis
[11, 12]; data on these etiologies in East-African chil-
dren, however, are still scarce [13, 14].
Fine needle aspiration biopsy (FNAB), an inexpensive,
easy-to-perform outpatient procedure, has become the
diagnostic approach of choice for children with persist-
ent lymphadenitis and is suited for primary health care
[15–17]. Diagnostic microscopy is used for cytology, for
smears after Ziehl-Neelsen (ZN) staining, and for auto-
fluorescence detection on Papanicolaou stained smears.
If combined, these three modalities have a reasonably
high sensitivity and specificity compared to culture [18].
However, neither culture nor microscopy-based diagnos-
tic approaches are considered a gold standard for TB
lymphadenitis. These tests are still rarely used in periph-
eral facilities of resource-poor settings: culture is com-
plex and implicates a high biosafety level; interpretation
of cytology requires advanced technical expertise and
small laboratories are often not equipped with fluores-
cence or light-emitting diode (LED) microscopes.
Automated and isothermal nucleic acid amplification
tests (NAAT), designed for use at low biosafety levels,
could offer promising alternatives for point-of-care diag-
nosis of TB lymphadenitis.
Xpert® MTB/RIF (Cepheid, Sunnyvale, USA) is an auto-
mated, cartridge-based NAAT for the detection of M. tu-
berculosis complex and rifampicin drug-resistance from
sputum and other specimens, with a turnaround time of
less than two hours [19, 20]. A WHO policy statement
from 2013 formulated recommendations to guide the use
of the test for pulmonary and extrapulmonary TB in adults
and children. Based so far only on very low evidence, Xpert
has been conditionally recommended as a replacement test
for usual practice (including conventional microscopy,
culture or histopathology) for testing specific non-
respiratory specimens, including lymph nodes [21].
The EasyNAT™ TB Isothermal Amplification Diagnostic
Kit (short form: EasyNAT; Ustar, Biotechnologies Co. Ltd,
Hangzhou, China) is an assay that uses isothermal cross-
priming amplification technology for the qualitative detec-
tion of M. tuberculosis [22]. The tool was approved for de-
tection of pulmonary TB by the China Food and Drug
Administration in 2014 [23]. Up to now, no studies have
been published on EPTB diagnosis using EasyNAT.
The aim of our study was to compare the diagnostic
performance of Xpert MTB/RIF and EasyNAT with
acid-fast bacilli (AFB) microscopy, cytology and myco-
bacterial culture for the diagnosis of TB lymphadenitis
in children from a TB-endemic setting in Tanzania.
Methods
Recruitment and clinical assessment
This prospective study was carried out from April 2012
until August 2013 at the Temeke District Hospital in
Dar es Salaam, Tanzania. Children older than 8 weeks
and younger than 16 years of age, suspected of having
TB lymphadenitis as defined by WHO [24], were re-
cruited. Inclusion criteria were: one or more palpable
lymph nodes of 1 cm or more persisting for more than
4 weeks in-spite of oral antibiotic therapy and a strong
clinical suspicion or microbiological confirmation of
mycobacterial infection. Children who had received TB
treatment in the preceding 12 months were excluded
from the study. All participants were clinically assessed
and treated according to current versions of the Tanza-
nian National TB and Leprosy Program (NTLP) guide-
lines [25, 26]. For children up to 6 years of age, the
clinical assessment was based on the NTLP clinical scor-
ing chart. Results from the evaluated diagnostic ap-
proaches also had an impact on treatment decisions.
At enrolment, clinical assessment comprised chest X-
ray in a frontal view, TST, full blood count and HIV test-
ing with pre- and post-test counselling. The HIV rapid
testing algorithm followed national guidelines [27]. HIV
DNA nucleic acid test was done for children between
8 weeks and 18 months of age, while for older children
antibodies to HIV were detected using rapid tests or En-
zyme Immunoassays. FNAB was performed on all partic-
ipants. Expectorated sputa were collected from children
with productive cough and sent for AFB microscopy to
the district laboratory. At a follow-up visit (time after re-
cruitment: 5–12 months; median 5 months), participants
were assessed for treatment outcomes and referred for
further treatment, if necessary.
Palpation-guided fine needle aspiration biopsy
Palpation-guided FNAB was carried out by trained med-
ical officers on palpable regional lymph nodes. FNAB
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was performed with a 23-gauge needle attached to a
10 mL syringe. The skin around the lymph node was
cleaned with an alcohol swab, the child was held firmly
and the node was stabilized while aspiration was per-
formed, with not more than 2 mL of suction.
Two smears were prepared from the first aspirate.
One smear was immediately fixed in 95 % ethanol solu-
tion for Papanicolaou staining for cytological assessment
and the other was air-dried and fixed in 100 % methanol
for ZN staining. The residue in needle and syringe was
rinsed in mycobacterial growth indicator tube (MGIT)
medium for mycobacterial culture with standard
PANTA antibiotic/growth supplement (Beckton Dickin-
son, Sparks, USA) [28]. The MGIT tube was transported
at ambient temperature to the laboratory for incubation
and further processing.
From the same lymph node, a second aspiration was
performed and rinsed into 0.7 ml sterile phosphate buff-
ered saline (PBS), pre-prepared in 1.5 ml polypropylene
tubes. These were transported to the laboratory at 4-8 °
C for NAAT testing. Laboratory personnel involved in
Xpert MTB/RIF and EasyNAT testing were blinded to
other results.
Laboratory diagnosis
FNA microscopy/cytology
The pathologist reported ZN stained smears as; “AFB
seen” or “no AFB seen”. Cytology results were cate-
gorised as “confirmed mycobacterial lymphadenitis”
(visualization of AFB), “suspected mycobacterial lymph-
adenitis” (signs of TB necrosis and granuloma consistent
with mycobacterial infection), nonspecific “reactive
lymphadenopathy” or “suspicion of malignancy” [29].
FNA TB culture
The inoculated MGIT tubes were incubated at 37 °C for
a maximum of 8 weeks. Positive MGIT cultures were
tested for contamination on blood agar. MPT64 antigen
and molecular tests as needed (GenoType® MTBDRplus
system and GenoType MTBC, Hain Lifescience GmbH,
Germany) were used for confirmation of M. tuberculosis
complex and identification of MTBC species, including
M. bovis BCG. Drug susceptibility testing (DST) was
done as described in the BACTEC MGIT 960 product
insert (Becton Dickinson) [30]. Non-tuberculous myco-
bacteria (NTM) were assessed using a reverse line-probe
assay (GenoType® Mycobacterium CM/AS, Germany).
FNA Xpert MTB/RIF testing
One half of the aspirate in PBS (0.2 to 0.7 ml) per par-
ticipant was filled up to 2.2 ml with Xpert MTB/RIF
sample reagent and incubated for 15 min, prior to dis-
pensing 2 ml of the mixture into a Xpert MTB/RIF. The
cartridge was loaded into the Xpert MTB/RIF
instrument for automated sample and real-time poly-
merase chain reaction (RT-PCR) processing. The instru-
ment reported the presence or absence of M.
tuberculosis complex, a semiquantitative estimate of M.
tuberculosis complex concentration (high, medium, low,
and very low) and the presence or absence of rifampicin
resistance.
FNA EasyNAT testing
The other half of the aspirate in PBS was processed ac-
cording to the EasyNAT testing protocol for specimens
other than sputum [31]. Very viscous or purulent speci-
mens were first treated with liquefying buffer provided,
according to the protocol for sputum specimens. The
DNA extracted for each sample was then prepared for
amplification and incubated at 63 °C for 60 min [31].
Detection of amplified products was performed on a lat-
eral flow strip, housed in an enclosed sealed plastic de-
vice, to prevent leakage of amplicons. Results were
visualized after 20 to 30 min. Appearance of the control
band alone indicated that the test was valid but that
there was no M. tuberculosis, or that the amount of M.
tuberculosis DNA was below the detection limit. In con-
junction with a visible control band, positivity was deter-
mined by the intensity of the test band in relation to an
intensity scale provided [31].
Statistical analysis
Sensitivity, specificity and Cohen’s Kappa [32] were cal-
culated for each and for all diagnostic modalities com-
bined with culture and cytology as single reference
standards, and with culture and cytology combined (M.
tuberculosis positive when either was positive and M. tu-
berculosis negative when both were negative), as a com-
posite reference standard (CRS). The calculations were
performed only for patients without missing data for the
respective modalities. Kappa (k) of more than 0.6 indi-
cated substantial to almost-perfect agreement with the
reference standard. Latent class analysis (LCA), a statis-
tical method for finding subtypes of related (latent) cases
from multivariate categorical data, was performed on all
the FNAB diagnostic outcomes. For each diagnostic mo-
dality, two classes were identified, 1 for TB positive and
2 for TB negative. Blank cells indicated inconclusive out-
comes or missing data. The LCA provided estimates of
the probability of M. tuberculosis-presence or M. tuber-
culosis-absence per case, based on the data input. Add-
itionally, a mixed logistic regression model with a 5-
dimensional binary outcome defined by the results of
the 5 test modalities was applied. The model included a
random subject intercept and assigned each subject the
empirical Bayes estimate of this random effect as a TB-
score, which was then correlated with each binary test.
Analyses were done using SAS version 9.2 (SAS Institute
Bholla et al. BMC Infectious Diseases  (2016) 16:246 Page 3 of 9
Inc., Cary, NC, USA) and Stata version 12.1 (StataCorp,
College Station, Texas, USA).
Results
A total of 79 children were recruited into this study; 4
children were excluded from analysis because of incom-
plete data due to death after recruitment, loss of contact,
relocation and subsiding lymph node more than 4 weeks
after general antibiotic treatment. During the recruit-
ment phase, a standard 6-month anti-TB regimen was
started in 57 participants based on NTLP paediatric TB
scoring (for children <6 years of age) or clinical assess-
ment (for children ≥6 years of age) and in 6 participants
based solely on laboratory test results, i.e. cytology,
Xpert MTB/RIF or culture. Participants who did not re-
ceive TB treatment (n = 12) were reviewed by the in-
ternal medicine, surgery or oncology departments. At
the follow up visit, the lymphadenitis was resolved in
33/34 children who had completed the anti-TB therapy
and 3/6 children who completed alternative therapy
(surgical intervention, fungal or antibiotic treatment).
Figure 1 displays the patient flow and clinical outcomes.
More boys than girls were recruited (61 % vs. 39 %).
The HIV prevalence was 20 %. Only 2 participants, 4
and 11 years of age, had a history of TB. At recruitment
one of the three children with additional productive
cough was found to be sputum AFB positive. Table 1
summarizes the participant characteristics.
The frequency of results from the different diagnostic
techniques on FNAB is shown in Table 2. In summary,
cytology results in 18 children (24 %) were consistent
with mycobacterial infection including 3 children with
ZN-positive lymphadenitis. M. tuberculosis was identi-
fied in 7 children (9 %) by culture. Mycobacterium bovis
BCG was isolated from 2 HIV negative children (3 %)
who were 3 and 4 months of age. Xpert MT/RIF was
positive in 14 (19 %) and EasyNAT in 5 (7 %) partici-
pants. There were no invalid Xpert MTB/RIF or Easy-
NAT results. No resistance was detected by Xpert MTB/
RIF or phenotypic DST.
Figure 2 displays the correlation between the different
laboratory testing modalities reporting cases as positive
for TB. The culture results comprise both samples with
confirmation of M. tuberculosis (n = 7) and M. bovis
BCG (n = 2). In 25 children, the diagnosis ‘TB lymph-
adenitis’ was confirmed by at least one of the diagnostic
modalities; of which 12 cases were positive by a single
diagnostic modality alone.
The performance of each laboratory diagnostic modal-
ity was assessed against culture as the reference standard
for TB. Due to the low positivity and high contamination
rates for culture in this study, cytology was considered
Fig. 1 Patient enrolment flow chart and clinical outcomes
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as an alternative reference standard. Additionally, a com-
posite reference standard, combining culture and cy-
tology results, was used to assess the performance of the
diagnostic tests (Table 3). Xpert MTB/RIF detected TB
lymphadenitis with a sensitivity and specificity of 56 and
96 %, 69 and 93 %, 58 and 93 % against a reference
standard consisting either of culture, or cytology, or cul-
ture and/or cytology respectively. The corresponding
sensitivity and specificity values for EasyNAT were 22
and 100 %, 22 and 100 %, and 19 and 100 %. The cat-
egory “any diagnostic modality” aimed to assess the per-
formance of a diagnostic algorithm including all the
modalities except those used as reference standard. The
sensitivity of “any diagnostic modality” were either equal
or superior compared to single tests, while the specificity
of “any diagnostic modality” at 93 % was below specifi-
city values of some single tests.
The agreement of each diagnostic modality with the
appointed reference standard (Cohen’s Kappa – k) is also
described in Table 3. Xpert MTB/RIF, compared to Easy-
NAT, showed a better agreement with TB culture (k =
0.58 vs. 0.31), cytology (k = 0.64 vs. 0.29) and the CRS (k
= 0.55 vs. 0.24). ZN microscopy had a poor agreement
with the three reference standards.
For LCA two ‘latent classes’ were generated: class 1
for TB-positive (prevalence of TB lymphadenitis in the
study population) with a probability of 22.8 % and class
2 for TB-negative with a probability of 77.2 %. The prob-
ability of a positive test result given membership to class
1 (i.e., the sensitivity) was high for cytology (100 %),
culture (74 %), Xpert MTB/RIF (71 %), but low for Easy-
NAT (29 %) and ZN (19 %). Conversely, the probability
of a negative test result given membership to class 2
(i.e., the specificity) was high for all 5 tests, with 100 %
for EasyNAT and ZN, 95 % for Cytology, 94 % for Xpert
MTB/RIF and 90 % for culture.
The mixed logistic regression model returned a TB-
score for each patient. The correlation of this score with
each binary test showed that cytology performed best
with a correlation of r = 0.87, followed by culture and
Xpert MTB/RIF at par (r = 0.82), EasyNAT (r = 0.60) and
ZN (r = 0.42).
Positive laboratory test results were analysed in rela-
tion to results of the paediatric score chart for children
below 6 years of age and to clinical assessment for the
older children (Table 4). By assessing the agreement to
score or clinical assessment, the true-positive rates for
all of the five modalities ranged between 5 and 26 % and
false-positive rates between 8 and 33 %.
Table 1 Participant characteristics
Characteristics at recruitment Children included in
study (N = 75) n (%)
Age (years)
0 to≤ 2 14 (19 %)
2 to≤ 6 30 (40 %)
6 to≤ 10 16 (21 %)
10 to ≤16 15 (20 %)
Gender
Male 46 (61 %)
HIV status
HIV test positive 15 (20 %)
HIV test negative 54 (72 %)
Unknown/missing/not done 6 (8 %)
TB contact in last 12 months
Yes 18 (24 %)
General clinical condition
Good 55 (73 %)
Reduced 15 (20 %)
Ill 5 (7 %)
Table 2 Frequency of laboratory findings on FNAB
Diagnostic modalities Children included in
study (N = 75) n (%)
Cytology
Consistent with mycobacterial infectiona 18 (24 %)
Reactive lymphadenopathy (negative) 39 (52 %)
Malignancy/suspected malignancy (negative) 4 (5 %)
Unsuitable for analysis 14 (19 %)
Missing -
Ziehl Neelsen microscopy
Acid fast bacilli-positive 3 (4 %)
Negative 71 (95 %)
Missing slide 1 (1 %)
Culture
M. tuberculosis 7 (9 %)
M. bovis BCG 2 (3 %)
Negative 29 (39 %)
Non-tuberculous mycobacteria (negative) 1 (1 %)
Contaminated 36 (48 %)
Missing -
Xpert MTB/RIF
Positive 14 (19 %)
Negative 56 (74 %)
Missing result 5 (7 %)
EasyNAT
Positive 5 (7 %)
Negative 70 (93 %)
Missing -
a Consistent with mycobacterial infection’ includes confirmed TB (AFB seen)
and/or suspected TB (morphological features consistent with TB infection –
caseating necrosis and granuloma)
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Discussion
We assessed the performance of Xpert MTB/RIF and of
EasyNAT for the diagnosis of paediatric TB lymphadenitis,
using culture or cytology as single reference standards and
a combination of both as a composite reference standard.
The results differed considerably between the two NAATs
under evaluation. Xpert MTB/RIF performed with a mod-
est sensitivity and good specificity, while the sensitivity of
EasyNAT was comparatively poor, with excellent specificity.
Both Xpert MTB/RIF and EasyNAT may have been nega-
tive in some cases of lymphadenitis caused by NTM infec-
tion, which is frequently seen in East Africa [11], but might
be undetected in our study due to the high proportion of
contaminated cultures. These results were consistent with a
Cohen’s kappa statistic, which showed a superior agreement
of Xpert MTB/RIF with TB culture, cytology and the CRS
compared to EasyNAT.
As an alternative to the CRS approach, a latent class ana-
lysis was applied to estimate the sensitivity and specificity
of diagnostic tests by linking multiple test results to the
same latent categories. This latent class model was used be-
cause of the imperfect or missing reference standard [33].
The LCA revealed superior sensitivity estimates for Xpert
MTB/RIF compared to EasyNAT (71 % versus 29 %). Con-
versely, the specificity estimates for EasyNAT were to some
extent higher than those for Xpert MTB/RIF (100 % versus
94 %). Interestingly, LCA indicated an excellent sensitivity
(100 %) and good specificity (95 %) for cytology.
Fig. 2 Venn diagram of TB positive results from all diagnostic modalities for FNAB. Diagram shows positive results from culture (including M.
tuberculosis and M. bovis BCG), Cytology, Xpert MTB/RIF and EasyNAT. The 3 AFB positive ZN smears are indicated by #
Table 3 Test performance and agreement of diagnostic modalities
Culture as reference standard Cytology as reference standard Composite reference standard:
culture and/or cytology
Sensitivitya Specificitya Cohen’s
Kappa
Sensitivitya Specificitya Cohen’s
Kappa
Sensitivitya Specificitya Cohen’s
Kappa
n/N n/N k n/N n/N k n/N n/N k
Cytology 6/9 67 % 22/24 92 % 0.60 - - - - - - - - - -
Culture - - - - - 6/8 75 % 22/25 88 % 0.60 - - - - -
ZN 1/9 11 % 24/25 96 % 0.10 3/18 17 % 43/43 100 % 0.22 3/21 14 % 41/41 100 % 0.18
Xpert 5/9 56 % 26/27 96 % 0.58 11/16 69 % 38/41 93 % 0.64 11/19 58 % 40/43 93 % 0.55
EasyNAT 2/9 22 % 30/30 100 % 0.31 4/18 22 % 43/43 100 % 0.29 4/21 19 % 46/46 100 % 0.24
Any diagnostic
modality
6/9 67 % 28/30 93 % 0.62 18/18 100 % 40/43 93 % 0.89 13/21 62 % 38/41 93 % 0.58
aCalculated only for patients without missing data
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A systematic review and meta-analysis of 13 studies de-
scribed a pooled sensitivity and specificity of 83.1 and
93.6 % for the Xpert MTB/RIF assay with TB culture as a
reference standard for the diagnosis of lymph node TB
[34]. This publication ultimately informed WHO policy
and has led to recommendations on the use of Xpert
MTB/RIF, over established tests, for diagnosis of TB in
lymph nodes in adults and children [35]. An additional
meta-analysis which also examined Xpert MTB/RIF
against TB culture for the diagnosis of TB lymphadenitis
showed a slightly better pooled sensitivity (87 %) and a
similar specificity (92 %) [36]. A hospital-based South Af-
rican FNAB study in 72 children by Coetzee et al. reported
a sensitivity of 80 % and a specificity of 93.8 % against a
CRS (cytology suggestive of mycobacterial disease with
visualization of the bacillus and/or positive TB culture)
[37]. In contrast to mentioned meta-analyses which fo-
cused primarily on adults and the evaluation on children
from South Africa, our Xpert MTB/RIF study in children
showed substantially lower estimates for sensitivity, but
similar estimates for specificity. The limited sensitivity of
Xpert MTB/RIF is most likely caused by the paucibacillary
nature of lymphatic TB manifestations in children [38] or
by suboptimal rinsing of needle passes [37].
The findings underscore the need for larger and repre-
sentative paediatric accuracy studies for the diagnosis of
mycobacterial lymphadenitis by Xpert MTB/RIF and other
NAATs. In the future, more sensitive, point-of-care NAAT,
which are also able to perform resistance testing, are re-
quired to make an impact over current modalities with re-
gard to mortality caused by paediatric and extrapulmonary
TB, as described in a recent modelling study [39].
Until now, EasyNAT, a manual assay based on isother-
mal cross-priming amplification, has only been evaluated
for the detection of pulmonary TB in adults [40, 41].
These two studies reported sensitivity for M. tuberculosis
detection against culture of 84.1 and 66.7 %, and specifi-
city of 97.8 and 100 %. Sensitivity in these studies was
further reduced when only smear-negative but culture-
positive pulmonary TB cases were tested (59.8 and 10 %)
which indicates a suboptimal limit of detection that
probably could explain the poor sensitivity with our
paediatric patients, where low density of mycobacteria is
expected in lymph nodes.
A major limitation of this study was the relatively high
proportion of invalid test results; i.e. 19 % of the samples
sent for cytology were not suitable for analysis and 48 % of
the TB cultures were contaminated. Consequently, the
comparison between diagnostic modalities was often re-
stricted to a small number of participants with valid results.
The high contamination rate negatively impacted the abso-
lute number of positive TB cultures and therefore reduced
the value of TB culture as a reference standard in FNAB.
The greatest promise of NAATs for the detection of
TB in lymph nodes of children is fast and accurate diag-
nosis, combined with simultaneous resistance testing.
The incomplete overlap of the different diagnostic mo-
dalities suggests that neither Xpert MTB/RIF nor Easy-
NAT currently seem to be appropriate as a single NAAT
to diagnose TB lymphadenitis in children.
Conclusions
Based on our findings, a promising diagnostic algorithm
for suspected childhood TB lymphadenitis seems to con-
sist of the combination of clinical assessment according
to WHO guidelines [17], cytology and Xpert MTB/RIF.
However, larger studies in children from different set-
tings are needed to prove this diagnostic concept. Easy-
NAT seems to be not suitable for diagnosis of TB
lymphadenitis in children. At high healthcare levels, TB
culture might be a valuable method for differentiation
between M. tuberculosis and M. bovis BCG, which is im-
portant for management of patients with lymphadenitis,
but its broader use is restricted due to the length of time
needed to get results, technical complexity, high costs
and biosafety requirements.
Table 4 FNAB laboratory diagnoses compared to clinical assessment
Paediatric score <6 years of age (n = 44) Clinical assessment ≥6 years of age (n = 31)
Score ≥7 (anti-TB therapy
recommended)
Score <7 (anti-TB therapy not
recommended)
Anti-TB therapy
recommended
anti-TB therapy not
recommended
n n = 38 n = 6 n = 19 n = 12
Positive
culture
9 5 (13 %) 1 (17 %) 3 (16 %) -
Positive
cytology
18 9 (24 %) 2 (33 %) 5 (26 %) 2 (17 %)
Positive Xpert 14 5 (13 %) 2 (33 %) 5 (26 %) 2 (17 %)
Positive
EasyNAT
5 2 (5 %) - 2 (11 %) 1 (8 %)
Positive ZN 3 2 (5 %) - 1 (5 %) -
Percentages in columns for ‘anti-TB therapy recommended’ are true-positive rates
Percentages in columns for ‘anti-TB therapy not recommended’ are false-positive rates
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